Ray Rajdeep, Das Stutee, Birangal Sumit Raosaheb, Boshoff Helena I, Roma Jose Santinni, Lobo Manisha, Hariharapura Raghu Chandrashekhar, Shenoy G Gautham
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Future Med Chem. 2025 Jan;17(1):19-34. doi: 10.1080/17568919.2024.2444872. Epub 2024 Dec 25.
This research aimed to develop novel indole-2-carboxamides as potential antitubercular agents using rational drug design. It also focused on identifying the critical interactions required for these compounds to exhibit effective antitubercular activity.
Novel indole-2-carboxamides targeting MmpL3 were designed based on SAR, synthesized, and tested for their antitubercular and induction properties. Classical docking and simulated annealing were utilized to understand protein-ligand binding affinity.
Compounds 5c, 5f, and 5i, were active against H37Rv and different MDR and XDR strains of promoter induction study indicated that those were inhibitors of MmpL3. Through the docking and simulated annealing studies, we identified key protein-ligand interactions at the MmpL3 binding site.
We have identified three potent antitubercular molecules that supposedly act via inhibiting MmpL3. Results from the molecular modeling studies can be used in future drug designing.
本研究旨在利用合理药物设计开发新型吲哚 - 2 - 甲酰胺作为潜在的抗结核药物。它还着重于确定这些化合物展现有效抗结核活性所需的关键相互作用。
基于构效关系设计了靶向MmpL3的新型吲哚 - 2 - 甲酰胺,进行合成,并测试其抗结核和诱导特性。利用经典对接和模拟退火来了解蛋白质 - 配体结合亲和力。
化合物5c、5f和5i对H37Rv以及不同的耐多药和广泛耐药菌株具有活性。启动子诱导研究表明这些是MmpL3的抑制剂。通过对接和模拟退火研究,我们确定了MmpL3结合位点处关键的蛋白质 - 配体相互作用。
我们已鉴定出三种可能通过抑制MmpL3起作用的强效抗结核分子。分子建模研究的结果可用于未来的药物设计。